Compare Stocks: QNRX, ADXS, MIRA, and TAOX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
MIRA MIRA Pharmaceuticals	$0.71 -1.4%	$0.78	$0.60 ▼ $2.45	$30.21M	1.48	290,727 shs	94,813 shs
QNRX Quoin Pharmaceuticals	$4.65 -1.5%	$5.71	$3.25 ▼ $41.80	$9.34M	1.56	296,283 shs	5,701 shs
TAOX Synaptogenix	$4.53 +3.1%	$3.84	$3.07 ▼ $10.00	$34.00M	1.73	156,797 shs	130,296 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,712.46%
MIRA MIRA Pharmaceuticals	-14.42%	-13.88%	-15.93%	-23.48%	-45.23%
QNRX Quoin Pharmaceuticals	+3.51%	-26.02%	-27.50%	+3.06%	-34.72%
TAOX Synaptogenix	-3.09%	-1.79%	+14.32%	+19.95%	-30.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
MIRA MIRA Pharmaceuticals	$0.71 -1.4%	$0.78	$0.60 ▼ $2.45	$30.21M	1.48	290,727 shs	94,813 shs
QNRX Quoin Pharmaceuticals	$4.65 -1.5%	$5.71	$3.25 ▼ $41.80	$9.34M	1.56	296,283 shs	5,701 shs
TAOX Synaptogenix	$4.53 +3.1%	$3.84	$3.07 ▼ $10.00	$34.00M	1.73	156,797 shs	130,296 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,712.46%
MIRA MIRA Pharmaceuticals	-14.42%	-13.88%	-15.93%	-23.48%	-45.23%
QNRX Quoin Pharmaceuticals	+3.51%	-26.02%	-27.50%	+3.06%	-34.72%
TAOX Synaptogenix	-3.09%	-1.79%	+14.32%	+19.95%	-30.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	2.33	Hold	$3.50	390.88% Upside
QNRX Quoin Pharmaceuticals	2.33	Hold	$20.00	330.20% Upside
TAOX Synaptogenix	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNRX, ADXS, MIRA, and TAOX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	QNRX Quoin Pharmaceuticals	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00
9/17/2026	MIRA MIRA Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.50
8/20/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	QNRX Quoin Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	TAOX Synaptogenix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$3.24M	11.05	N/A	N/A	($2.06) per share	-0.29
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.25 per share	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$15.64 per share	N/A
TAOX Synaptogenix	$300K	112.85	N/A	N/A	$2.83 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	-$48.07M	-$5.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	-$10.44M	-$1.24	N/A	N/A	N/A	N/A	-106.95%	-104.18%	12/2/2026 (Estimated)
QNRX Quoin Pharmaceuticals	-$15.81M	-$25.18	N/A	N/A	N/A	N/A	-489.57%	-221.17%	11/5/2026 (Estimated)
TAOX Synaptogenix	-$28.74M	-$3.85	N/A	N/A	N/A	-2,153.97%	-128.51%	-97.54%	N/A

Latest QNRX, ADXS, MIRA, and TAOX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	QNRX Quoin Pharmaceuticals	-$1.61	-$1.90	-$0.29	-$1.90	N/A	N/A
8/13/2026	Q2 2026	TAOX Synaptogenix	N/A	-$1.83	N/A	-$1.83	N/A	$0.09 million
8/12/2026	Q2 2026	MIRA MIRA Pharmaceuticals	N/A	-$0.03	N/A	-$0.03	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	200.08	200.08
QNRX Quoin Pharmaceuticals	N/A	1.76	1.76
TAOX Synaptogenix	N/A	19.98	19.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
MIRA MIRA Pharmaceuticals	35.16%
QNRX Quoin Pharmaceuticals	8.63%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
MIRA MIRA Pharmaceuticals	19.89%
QNRX Quoin Pharmaceuticals	11.17%
TAOX Synaptogenix	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	20	59.31 million	42.36 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	42.02 million	33.66 million	Not Optionable
QNRX Quoin Pharmaceuticals	6	2.01 million	1.78 million	Not Optionable
TAOX Synaptogenix	4	7.48 million	7.28 million	N/A

QNRX, ADXS, MIRA, and TAOX Headlines

Recent News About These Companies

Synaptogenix (NASDAQ:TAOX) Upgraded to Hold at Wall Street Zen

September 26, 2026 | americanbankingnews.com

TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor

July 8, 2026 | prnewswire.com

TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI

June 16, 2026 | prnewswire.com

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

November 18, 2025 | prnewswire.com

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

November 11, 2025 | prnewswire.com

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

November 4, 2025 | prnewswire.com

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

October 20, 2025 | prnewswire.com

TAO Synergies Announces $11 Million Private Placement

October 13, 2025 | prnewswire.com

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

September 22, 2025 | prnewswire.com

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

September 8, 2025 | prnewswire.com

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

July 1, 2025 | prnewswire.com

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

June 26, 2025 | prnewswire.com

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN Austin

June 26, 2025 | kxan.comK

Synaptogenix begins TAO acquisition as part of crypto treasury strategy

June 26, 2025 | uk.investing.com

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLA

June 26, 2025 | ktla.comK

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

June 24, 2025 | prnewswire.com

Synaptogenix Unveils TAO-Focused Crypto Treasury Plan

June 10, 2025 | livebitcoinnews.comL

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

June 9, 2025 | prnewswire.com

Synaptogenix Inc Ordinary Shares

January 3, 2025 | morningstar.comM

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

December 20, 2024 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX, ADXS, MIRA, and TAOX Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

$0.60 0.00 (0.00%)

As of 10/1/2026

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

MIRA Pharmaceuticals NASDAQ:MIRA

$0.71 -0.01 (-1.38%)

As of 12:29 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Quoin Pharmaceuticals NASDAQ:QNRX

$4.65 -0.07 (-1.50%)

As of 12:23 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Synaptogenix NASDAQ:TAOX

$4.53 +0.14 (+3.10%)

As of 12:29 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNRX, ADXS, MIRA, and TAOX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNRX, ADXS, MIRA, and TAOX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNRX, ADXS, MIRA, and TAOX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX, ADXS, MIRA, and TAOX Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

MIRA Pharmaceuticals NASDAQ:MIRA

Quoin Pharmaceuticals NASDAQ:QNRX

Synaptogenix NASDAQ:TAOX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNRX, ADXS, MIRA, and TAOX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNRX, ADXS, MIRA, and TAOX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNRX, ADXS, MIRA, and TAOX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX, ADXS, MIRA, and TAOX Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

MIRA Pharmaceuticals NASDAQ:MIRA

Quoin Pharmaceuticals NASDAQ:QNRX

Synaptogenix NASDAQ:TAOX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools